2022: Schweikert Voted Against Authorizing $1 Million Annually Through FY 2027 For The National Institutes Of Health To Research Cardiovascular Diseases Among At-Risk Communities And Create An Online Resource Of Heart Health Research And Treatment Options. In July 2022, according to Congressional Quarterly, Schweikert voted against the South Asian Heart Health Awareness and Research Act of 2022, which would "authorize $1 million annually through fiscal 2027 for the National Institutes of Health to conduct or support research on cardiovascular disease and related ailments among at-risk populations and to establish an online clearinghouse of heart health research and treatment options." The vote was on passage. The House passed the bill by a vote 237-192, thus the bill was sent to the Senate. The Senate did not take substantive action on the bill. [House Vote 398, 7/27/22; Congressional Quarterly, 7/27/22; Congressional Actions, H.R. 3771]
2024: Schweikert Voted To Reauthorize The National Institutes Of Health Pediatric Research Initiative Through FY 2028. In March 2024, Schweikert voted for , according to Congressional Quarterly, "the bill, as amended, that would reauthorize the Pediatric Research Initiative at the National Institutes of Health for five years, through fiscal 2028, at the prior authorization level of $12.6 million per year. Authorization for the program expired on Sept. 20, 2023. The bill would express the sense of Congress that the NIH director should continue to oversee and coordinate research conducted or supported by the NIH on pediatric cancer and other pediatric diseases and conditions. It would also add program language stating that the NIH must prioritize research that does not duplicate research activities that already exist." The vote was on passage. The House passed the bill by a vote of 384 to 4. [House Vote 60, 3/5/24; Congressional Quarterly, 3/5/24; Congressional Actions, H.R. 3391]